NCT04030962 - A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease | Biotech Hunter

Enrollment

292

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions

Dry Eye DiseaseDry Eye Syndrome

Interventions

DRUG

AGN-242428

Ophthalmic solution administered as a topical eye drop

DRUG

AGN-231868

Ophthalmic solution administered as a topical eye drop

OTHER

AGN-242428 Vehicle

Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop

OTHER

AGN-231868 Vehicle

Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop

DRUG

Lifitegrast 5% Ophthalmic Solution

Ophthalmic solution administered as a topical eye drop

Trial Locations (11)

16066

Scott and Christie and Associates /ID# 232746, Cranberry Township

24502

Piedmont Eye Center /ID# 232698, Lynchburg

28150

Vita Eye Clinic /ID# 232721, Shelby

37167

Advancing Vision Research /ID# 232660, Smyrna

40206

The Eye Care Institute /ID# 232683, Louisville

85032

Cornea and Cataract Consultants of Arizona /ID# 232769, Phoenix

92663-3637

The Eye Research Foundation /ID# 232696, Newport Beach

80907-7529

Vision Institute Central /ID# 239910, Colorado Springs

01810

Andover Eye Associates /ID# 232689, Andover

38119-5745

Total Eye Care, PA /ID# 232657, Memphis

84015-8562

Duplicate_Alpine Research Organization, Inc. /ID# 240508, Clinton